Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Naltrexone Therapeutics Inc.
Vancouver, Canada
- Ownership
- Private
- Development stage
- Other
01
Overview
Holds IP for transdermal delivery of naltrexone, aimed at improving bioavailability, regulating dosage, and reducing GI side effects for treating substance use disorders and potentially long COVID. No clinical results reported.
- Therapeutic areas
- PsychiatryInfectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
LOVE Pharma Co.
Beyond the preview
Go deeper on Naltrexone Therapeutics Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Naltrexone Therapeutics Inc..